お知らせ • Feb 11
Neurone Studio S.A. to Report Q4, 2025 Results on Feb 13, 2026 Neurone Studio S.A. announced that they will report Q4, 2025 results on Feb 13, 2026 Buy Or Sell Opportunity • Dec 16
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 27% to zł1.02. The fair value is estimated to be zł1.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 165% over the last 3 years. Earnings per share has grown by 26%. Buy Or Sell Opportunity • Dec 01
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 15% to zł1.10. The fair value is estimated to be zł1.42, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 165% over the last 3 years. Earnings per share has grown by 24%. お知らせ • Nov 11
Neurone Studio S.A. to Report Q3, 2025 Results on Nov 13, 2025 Neurone Studio S.A. announced that they will report Q3, 2025 results on Nov 13, 2025 New Risk • Sep 14
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł213k free cash flow). Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (zł3.87m market cap, or US$1.07m). Minor Risk Shareholders have been diluted in the past year (26% increase in shares outstanding). New Risk • Sep 06
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł213k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł213k free cash flow). Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (zł2.85m market cap, or US$786.9k). New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł324k free cash flow). Shares are highly illiquid. Negative equity (-zł141k). Revenue is less than US$1m. Market cap is less than US$10m (zł3.51m market cap, or US$868.5k). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). お知らせ • Jun 18
Neurone Studio S.A., Annual General Meeting, Jul 11, 2024 Neurone Studio S.A., Annual General Meeting, Jul 11, 2024. New Risk • Aug 25
New major risk - Negative shareholders equity The company has negative equity. Total equity: -zł6.8k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł329k free cash flow). Shares are highly illiquid. Negative equity (-zł6.8k). Revenue is less than US$1m (zł250 revenue, or US$60.0). Market cap is less than US$10m (zł4.39m market cap, or US$1.06m). Minor Risk Shareholders have been diluted in the past year (3.4% increase in shares outstanding). お知らせ • Jun 04
Neurone Studio S.A., Annual General Meeting, Jun 30, 2023 Neurone Studio S.A., Annual General Meeting, Jun 30, 2023, at 11:00 Central European Standard Time. Is New 90 Day High Low • Feb 12
New 90-day low: zł3.70 The company is down 21% from its price of zł4.70 on 13 November 2020. The Polish market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Entertainment industry, which is down 17% over the same period. Is New 90 Day High Low • Oct 21
New 90-day low: zł4.74 The company is down 18% from its price of zł5.75 on 23 July 2020. The Polish market is down 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Entertainment industry, which is down 3.0% over the same period. 
